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Abstract 
Background: Autophagy can either be protective and confer survival to stressed cells, or it can contribute to cell 
death. The antimitotic drug 2-ethyl-3-O-sulpamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) is an in silico-designed 
17-β-estradiol analogue that induces both autophagy and apoptosis in cancer cells. The aim of the study was to 
determine the role of autophagy in ESE-15-ol-exposed human adenocarcinoma breast cancer cells; knowledge that 
will contribute to future clinical applications of this novel antimitotic compound. By inhibiting autophagy and deter-
mining the cytotoxic effects of ESE-15-ol-exposure, deductions could be made as to whether the process may confer 
resistance to the drug, or alternatively, contribute to the cell death process.
Methods and results: Spectophometrical analysis via crystal violet staining was used to perform cytotoxicity studies. 
Morphology studies were done using microscopic techniques namely polarization-optical transmitted light differ-
ential interference light microscopy, fluorescent microscopy using monodansylcadaverine staining and transmission 
electron microscopy. Flow cytometry was used to quantify the autophagy inhibition and assess cell viability. Results 
obtained indicated that 3-methyladenine inhibited autophagy and increased cell survival in both MCF-7 and MDA-
MB-231 cell lines.
Conclusion: This in vitro study inferred that autophagy inhibition with 3-methyladenine does not confer increased 
effectiveness of ESE-15-ol in inducing cell death. Thus it may be concluded that the autophagic process induced by 
ESE-15-ol exposure in MCF-7 and MDA-MB-231 cells plays a more significant role in cell death than conferring survival.
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Background
2-Methoxyestradiol (2ME), a microtubule depolymeris-
ing agent, is both an anti-cancer and anti-angiogenic drug 
that has shown promise in cancer research (Fig. 1a) [1–3]. 
Although it is formed through the sequential endogenous 
metabolism of 17-β-estradiol, the compound exerts its cyto-
toxic effect independently of the cellular estrogen receptors 
and has no significant systemic hormonal effects [1–4]. 2ME 
is able to inhibit cancer cell proliferation, whereas estradiol 
promotes proliferation of cancer cells. 2ME inhibits hypoxia-
inducible factor-1α (HIF-1α) which, in return causes inhibi-
tion of angiogenesis, as well as disruption of microtubules 
[2, 5]. 2ME causes both the intrinsic- and extrinsic apoptotic 
pathways to be up-regulated by decreasing B-cell lymphoma 
2 (Bcl-2) which has anti-apoptotic properties, or by increas-
ing the death receptor 5 (DR5) [2, 5]. Actively proliferating 
cells, such as cancer cells, are the main target for this drug-
induced apoptosis while preferential sparing of normal, 
quiescent endothelial cells is observed [3, 6]. 2ME not only 
causes a G1 cell cycle arrest, but also a G2/M arrest [3, 7]. 
However, the molecular mechanism induced by 2ME differs 
between cell lines [5]. 2ME has undergone clinical trials for 
solid tumors, but shows limited bioavailability and rapid deg-
radation in vivo [1–3, 8].
2-Ethyl-3-O-sulpamoyl-estra-1,3,5(10),15-tetraen-
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is a novel sulphamoylated estradiol analogue (Fig.  1b) 
[9]. ESE-15-ol is an anti-mitotic compound that binds 
to the colchicine binding site on microtubules, and is 
equally effective in both hormone-receptor positive- 
and negative cancer types [9–11]. ESE-15-ol induces 
both autophagy and apoptosis in breast cancer cells [9]. 
This potential anticancer drug was in silico-designed to 
increase the parent compound’s bioavailability via car-
bonic anhydrase II (CAII) binding by the addition of 
a sulphamate group at the C′3 position [9]. The latter 
enzymatic binding occurs in erythrocytes and results 
in a slower release of drugs into the circulation, thereby 
bypassing the hepatic first-pass metabolism [9, 12, 13]. 
Tumors have acidic micro-environments in which CAIX 
convert carbon dioxide (CO2) to carbonic acid [14]. This 
acidic environment enhances metastatic spread due to 
proteinase release [9, 15]. Therefore the molecule was 
designed to also have an increased binding affinity to 
CAIX over CAII. By binding to CAIX, ESE-15-ol should 
selectively locate to solid tumours and potentionally 
improve chemotherapy by reducing the acidic surround-
ing, thereby decreasing metastasis [9].
Apoptosis is an energy-dependant mode of cell death 
and is also known as programmed cell death type I 
[16–18]. If apoptosis is down-regulated it permits 
tumor growth and multi-drug resistance [18]. Type II-
programmed cell death is a degradative process known 
as autophagy which is associated with the formation of 
autophagic vesicles [19, 20]. Literature points at a possi-
ble dual role associated with autophagy since it can con-
tribute to either cell survival or cell death, depending on 
a myriad of different conditions [19, 20]. It may promote 
survival by facilitating an adaptive response to cellular 
stress through providing an alternative source of energy 
during starvation. Additionally, autophagy can increase 
cell survival by protecting them from apoptosis through 
the down-regulation of pro-apoptotic proteins [19]. 
However, prolonged autophagy can lead to cell death due 
to the high protein turnover rate [21]. Autophagy and 
apoptosis are interconnected and share common stim-
uli for the execution of both pathways. Apoptosis and 
autophagy can thus either have synergistic or antagonis-
tic effects [22].
3MA, a nucleotide derivative, is an inhibitor of 
autophagy [23]. 3MA blocks autophagy through inhibit-
ing class I and class III phosphatidylinositide-3-kinases 
(PI3K) [23, 24]. Class III PI3K is a lipid protein that 
phosphorylates the 3rd position on the inositol ring 
in phosphatidylinositol to form phosphatidylinositol-
3-phosphate (PI3P), which is essential for the initial steps 
in autophagy [23]. This leads to the activation of protein 
kinase B (Akt) which then phosphorylates the mechanis-
tic target of rapamycin (mTor) [20, 23]. 3MA can sup-
press cell invasion and migration of fibrosarcoma cells 
(HT1080) by inhibiting class III PI3K [25].
Studies by Xie et al. [27] and Li et al. [26] have shown 
that autophagy inhibition by 3-methyladenine (3MA) 
increased apoptotic cell death in human colon cancer cell 
lines and human hepatoma cells (HepG2). By inhibitiong 
the protective mechanism of autophagy, chemoresistance 
was overcome. However, Bonet-Ponce et al. [28] demon-
strated that inhibition of autophagy by 3MA inhanced 
cell survival through reducing the oxidative stress-
induced cell death. This indicates that the mechanisms of 
autophagy are cell and drug dependant.
In this study autophagy inhibition with 3MA dur-
ing ESE-15-ol exposure was conducted to allow insight 
into whether autophagy will confer resistance to drug-




Dulbecco’s minimum essential medium Eagle (DMEM), 
trypsin–EDTA, 3-methyladenine (3MA) and all other 
reagents not specifically mentioned were of analyti-
cal grade and purchased from Sigma-Aldrich (St. Louis, 
USA). Streptomycin, fungizone and penicillin were man-
ufactured by Thermo Fisher Scientific (Massachusette 
(MA), USA). Crystal violet, gluteraldehyde and triton 
X-100 were purchased from Merck (Darmstadt, Ger-
many). Anti-LC3B/MAP1LC3B-antibody was supplied 
by Novus Biological [Littleton, Colorado (CO), USA].
Chemical compounds and appropriate controls
The novel estradiol analogue, ESE-15-ol, was synthesized 
by Ithemba Pharmaceuticals (PTY) Ltd. (Modderfontein, 
Gauteng, South Africa) as it is not commercially avail-
able. A working 1  mM stock solution of ESE-15-ol in 
dimethyl sulfoxide (DMSO) was prepared at the Depart-
ment of Physiology, University of Pretoria and stored 
at −20  °C. DMSO was used as a vehicle control, never 
Fig. 1 Structure of 2-methoxyestradiol and ESE-15-ol. a 2-Methox-
yestradiol is the parent compound of ESE-15-ol; b ESE-15-ol is a novel 
sulphamoylated estradiol analogue
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exceeding a 0.05% concentration in the final dilution. 
Actinomycin D (Sigma-Aldrich, St Louis, USA) was used 
as a positive control for apoptosis at a final concentration 
of 0.1  μg/ml. A final concentration of 20  μM tamoxifen 
(Sigma-Aldrich, St Louis, USA) was used as a positive 
control for autophagy. Tamoxifen (20 μM) combined with 
5 mM 3MA was used as a positive control for autophagy 
inhibition. All chemicals were of analytical grade and 
purchased from Sigma-Aldrich (St Louis, USA), unless 
otherwise stated.
Cell lines and general cell culture protocols
For this in vitro study, the human adenocarcinoma breast 
cancer MCF-7 cell line and the metastatic human adeno-
carcinoma breast cancer MDA-MB-231 cell line were 
used (Cellonex, Johannesburg, South Africa). Penicil-
lin G (100  U/ml), fungizone (250  μg/l), streptomycin 
(100 μg/l) and 10% heat activated fetal calf serum (FCS) 
(Gibco® Invitrogen, California, USA) were added to 
DMEM. For the 96 well plates, 5000 cells were seeded in 
200  μl growth medium in each individual well. For the 
6 well plates, 375,000 cells were seeded in 3  ml growth 
medium in each individual well. For the 25  cm2 culture 
flasks, 1 ×  106  cells/5  ml growth medium were seeded. 
Cells were incubated in a Forma Scientific water-jacketed 
incubator (Ohio, USA) in a humidified atmosphere at 5% 
CO2 (37 °C) for 24 h before exposure to ESE-15-ol, with 
or without 3MA. A final concentration of 5  mM 3MA 
was used to inhibit autophagy during exposure with ESE-
15-ol or tamoxifen. Cells were pre-exposed to 3MA for 
an hour prior to addition of ESE-15-ol or tamoxifen.
Spectrophotometry: crystal violet
Crystal violet is a triarylmethane dye (purple) that stains 
the deoxyribonucleic acid (DNA) within cells in a mon-
olayer culture. Cytotoxicity of a drug may be determined 
by measuring the absorbance of the crystal violet stained 
cells via spectrophotometry. The half maximal growth 
inhibitory concentration (GI50) may thus be determined 
[29, 30]. After a 24 h-exposure to an ESE-15-ol dose con-
centration series, 100 μl 1% gluteraldehyde was added to 
the cells and samples were incubated for 15 min at room 
temperature. Gluteraldehyde was discarded and 100  μl 
0.1% crystal violet was added for 30 min for staining to 
take place. Crystal violet was discarded and the plate 
was washed under running tap water (±10  min). Plates 
were left to dry for 24 h. Triton X-100 (0.2%) (200 μl) was 
added to the wells and samples were incubated for 40 min 
at room temperature for solubilisation. After incubation, 
100  μl of the solution was pipetted to a clean 96 well 
plate. Absorbance was read using the ELx800 Universal 
Microplate Reader (Bio-tek Instruments Inc. Vermont, 
USA) at 570 nm.
Polarization‑optical transmitted light differential 
interference microscopy
Viable cells were seeded at a density of 375,000 cells/3 ml 
growth medium in 6 well plates. After attachment, cells 
were exposed to ESE-15-ol in the presence or absence of 
3MA for 24  h (37  °C) along with appropriate controls. 
PlasDIC images were viewed at a 40× magnification with 
a Zeiss Axiovert-40 microscope (Göttingen, Germany) 
and captured with the Zeiss Axiovert MRm monochrome 
camera (Göttingen, Germany).
Fluoresence microscopy
Cells were exposed to ESE-15-ol in the presence or 
absence of 3MA for 24 h (37°) along with the appropri-
ate controls. Cells were stained with 0.05  mM monod-
ansylcadaverine (MDC) in PBS for 10  min (37  °C) and 
protected against light after which cells were washed four 
times with PBS. Using the Zeiss inverted Axiovert CFL 40 
microscope and the Zeiss Axiovert MRm monochrome 
camera (Göttingen, Germany) fluorescent images were 
visualized with a UV filter with excitation of 380 nm and 
emission of 480 nm at a 40× magnification.
Transmission electron microscopy
After 24  h of exposure to ESE-15-ol with or without 
3MA alongside all the appropriate controls, cells were 
trypsinized and fixed in 2.5% gluteraldehyde in 0.075 M 
phosphate buffer for 1 h (room temperature). Cells were 
washed three times for 10 min with 0.075 M phosphate 
buffer followed by fixation in 0.5% aqueous osmium 
tetroxide for 1 h (room temperature). Cells were washed 
3 times in distilled water. Increasing ethanol concentra-
tions (10, 30, 50, 70 and 100%) were used to dehydrate 
the fixed cells for 10 min in each concentration. Quetol 
(30%) in ethanol was used to infiltrate the cells (1 h) fol-
lowed by 60% quetol (1 h) and lastly in 100% quetol (4 h). 
Specimen were embedded and polymerized (60 °C, 39 h). 
Ultra thin sections were prepared using a microtome and 
each section was mounted on a copper grid. Samples 
were contrasted in 4% aqueous uranyl acetate (10  min) 
and then in Reynolds lead citrate (2  min). To view the 
TEM images the JEM-2100F field emission transmission 
electron microscope (JEOL, Tokyo, Japan) was used. All 
Chemicals provided by the Electron Microscopy unit, 
University of Pretoria.
Cell cycle progression
Propidium iodide (PI) is a fluorescent dye used to quan-
tify DNA content at 488 nm excitation [31]. Flow cytom-
etry employing PI was used to distinguish cells in the 
different cell cycle phases. After exposure, cells were 
trypsinized and washed in 1 ml ice-cold PBS and resus-
pended in 200 μl ice-cold PBS. Cells were fixed in 4 ml 
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ice-cold 70% ethanol, added drop wise while vortexing 
and incubated overnight at 4  °C. Cells were centrifuged 
(5 min at 100×g) and the pellet resuspended in PBS con-
taining 0.01% triton X-100, PI (40  μg/ml) and RNase A 
(100 μg/ml) and incubated for 40 min at 37  °C. PI fluo-
rescence was measured using flow channel 3 (FL3) on the 
FC500 system flow cytometer (Beckman Coulter, Califor-
nia, USA) excited at 488 nm. A minimum of 10,000 cells 
were analized using three biological repeats. Cell cycle 
distributions were analized with Cyflogic flow cytometry 
analysis software (Beckman Coulter, California, USA) 
using the DNA content per cell which illustrates the sub-
G1, G1, S, G2/M fractions.
Apoptosis detection: annexin‑V FITC
Viable cells contain phosphatidylserine (PS), located on 
the inside of cell membrane. When apoptosis occurs, PS 
flip will occur. PS moves to the outside surface of cells 
to which annexin-V binds [32]. Washed cells were cen-
trifuged and the supernatant discarded. The pellet was 
resuspended in annexin-V FITC binding buffer (0.25–
107 cells/ml). Cell suspension (100 μl) was pipetted into a 
5 ml test tube. Annexin-V FITC (5 μl) and 10 μl of PI was 
added and samples were incubated at room temperature 
(15  min) in the dark. After incubation 400  μl annexin-
V binding buffer was added to each test tube. PI (FL3) 
and annexin-V (FL1) fluorescence was analyzed with the 
FC500 system flow cytometer (Beckman Coulter, Cali-
fornia, USA) equipped with an air-cooled argon laser 
excited at 488 nm. Three biological repeats with a mini-
mum of 10,000 cells were analized. Data was analyzed 
with Cyflogic flow cytometry analysis software (Beckman 
Coulter, California, USA) with PI plotted on the x-axis 
and annexin V-FITC on the y-axis.
Autophagy detection: microtubule‑associated protein 
1A/1B‑light chain 3
To detect autophagy, flow cytometry was used employ-
ing microtubule-associated protein 1A/1B-light chain 
3 (LC3) using a conjugated rabbit polyclonal anti-
LC3B antibody which can be detected in FL1 (excita-
tion = 488 nm; emission = 525 nm) [33]. After 24 h of 
exposure to ESE-15-ol with or without 3MA, washed 
trypsinized cells were resuspended in ice-cold PBS con-
taining 0.01% formaldehyde and samples were incu-
bated for 10  min at 4  °C. Cells were centrifuged and 
resuspended in 200 μl PBS to which 1 ml ice-cold 100% 
methanol was added and incubated for 15  min at 4  °C. 
Cells were washed twice with PBS. Cell pellet was resus-
pended in 200 μl PBS containing 0.05% triton X-100, 1% 
BSA, 40  μg/ml PI and anti-LC3B/MAP1LC3B-antibody 
(1:200) (Novus Biological, Littleton, CO, USA) and incu-
bated for 2 h at 4 °C. Cells were washed twice with 1 ml 
PBS containing 0.05% triton X-100 and 1% BSA. LC3 flu-
orescence was measured in flow channel 1 (FL1) on the 
FC500 system flow cytometer (Beckman Coulter, Califor-
nia, USA). Three biological repeats with a minimum of 
10,000 cells were used and data was analyzed with Cyf-
logic flow cytometry analysis software (Beckman Coulter, 
California, USA). Any cell debris and cell clumps were 
removed from analysis.
Western blot analysis: LC3II
After 24 h exposure, DMEM was aspirated and cells were 
washed with ice-cold PBS. 200  μl RIPA cell lysis buffer 
(150 mM NaCl, 0.1% SDS, 10 mM Tris–HCl 0.5% sodium 
deoxcylate, 1  mM EGTA and 1  mM EDTA in ddH20, 
adjusted to a pH of 7.4) was added to cells and incubated 
for 5 min on ice. Lysed cells were scraped and centrifuged 
for 30  min at 4  °C (1000×g). Protein concentration was 
determined by use of the Pierce® BCA protein assay kit 
(Thermo Fisher Scientific Inc., Rockford, Illinois, USA). 
In a 96 well plate, 20 μl of the cytosolic extract was added 
to 100  μl of the protein assay working solution. The 
absorbance was read at 570  nm by use of ELx800 Uni-
versal Microplate Reader (Bio-tek Instruments Inc. Ver-
mont, USA). The protein concentration was calculated 
by using a standard curve. After protein quantification 
25  μg protein of each sample, containing 5% b-mercap-
toethanol and NuPAGE LDS buffer (1:4) (Sigma-Aldrich, 
St. Louis, USA) was denaturated at 96 °C (10 min). Sam-
ples (20  μl) were loaded into NuPAGE 4–12% Bis–Tris 
gel wells alongside a relevant protein band size ladder. 
Samples were run in 1× MOPS buffer (190 mM Glycine, 
25 mM Tris and 0.1% SDS in ddH20, adjusted to a pH of 
8.3) at 120 V for 90 min for protein separation via electro-
phoresis. Separated proteins were transferred to a PVDF 
0.2  μm membrane (Amersham Hybond, GE Healthcare 
Life Sciences) in 1× transfer buffer (48 mM Tris, 39 mM 
glycine, 20% methanol and 0.0375% SDS), which was 
activated with 100% methanol. Wet transfer was achieved 
overnight at 40  V. After transfer, the membrane was 
blocked in 5  ml blocking buffer (2% BSA in 0.2% PBS-
TWEEN) for 30  min at room temperature. Membranes 
were incubated overnight at 4 °C in the primary antibody 
cocktail (1:1000 monoclonal LC3B/MAP1LC3B antibody 
produced in rabbit in 0.2% PBS-Tween, 2% BSA) pur-
chased from Novus Biological [Littleton, Colorado (CO), 
USA]. Membranes were washed three times in washing 
buffer for 15 min each. This was followed by 1 h incuba-
tion with the secondary antibody (anti-rabbit IgG anti-
body raised in goat labelled with horse-radish peroxidase 
(HRP) (1:10,000) (KPL, Mayland, USA) in 2.5% BSA in 
PBS. Membranes were washed three times in washing 
buffer for 15 min each. Pierce® ECL western blotting rea-
gent (Thermo Fisher Scientific, MA, USA) was used to 
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activate HRP activity to visualize proteins using Chemi-
Doc MP (Bio-Rad, CA, USA). Monoclonal anti-actin 
antibody produced in mouse (1:5000, Sigma-Aldrich, St. 
Louis, USA) was used to standardise the membranes and 
developed using the anti-mouse IgG secondary antibody 
raised in goat labelled with HRP (KPL, Mayland, USA). 
Image Lab 5.2.1 (Bio-Rad, CA, USA) was used to deter-
mine band size. Three biological repeats were done.
Statistical analysis
Morphology studies supplied qualitative data and crys-
tal violet staining and flow cytometry analysis supplied 
quantitative data. Flow cytometry was repeated 3 times 
and involved the analysis of at least 10,000 cells per 
run. Three independent experiments were performed 
and data were shown as the mean  ±  standard devia-
tion. Analysis of variance (ANOVA) single factor model 
of significance was used to statistically analyze data and 
followed by a two-tailed Student’s t-test. A statistical sig-
nificant P value of <0.05 was used and indicated with an 
asterisk (*) and (#) was used to indicate a statistically sig-
nificant difference between ESE-15-ol-exposed cells and 
those exposed in the presence of 3MA. Means are pre-
sented with bar-graphs with T-bars referring to standard 
deviations.
Results
Inhibition of autophagy decreases the cytotoxicity 
of ESE‑15‑ol as determined by spectrophotometry
Spectrophotometry was used to determine the effect 
of autophagy inhibition on the cytotoxicity of ESE-15-
ol-exposed human adenocarcinoma breast cancer cells 
(MCF-7) and metastatic human adenocarcinoma breast 
cancer cells (MDA-MB-231). The half maximum growth 
inhibitory concentrations (IG50) of ESE-15-ol with and 
without 3MA were determined by dose-dependent stud-
ies over a 24  h period. The IG50 of ESE-15-ol was cal-
culated at 0.05 ± 0.018 μM and at 0.15 ± 0.014 μM for 
ESE-15-ol with 3MA in MCF-7 cells (Fig.  2a). The IG50 
of ESE-15-ol was calculated at 0.065 ± 0.005 μM, and at 
0.13 ± 0.06 μM for ESE-15-ol with 3MA-exposed MDA-
MB-231 cells (Fig.  2b). Autophagy inhibition was thus 
seen to have caused a statistically significant decrease in 
ESE-15-ol cytotoxicity, with a P value of 0.007 in MCF-7 
cells and 0.0195 in MDA-MB-231 cells.
Morphological features of cell death induced by ESE‑15‑ol 
were atteniated by addition of 3MA
Polarization-optical transmitted light differential inter-
ference light microscopy (PlasDIC) was used to evaluate 
the morphological response of cells to ESE-15-ol with 
or without 3MA. MCF-7 (Fig.  3ai) and MDA-MB-231 
(Fig.  3aii) cells exposed to DMSO showed no signs of 
cell distress. Confluent cell growth was seen with vis-
ible nucleoli as for the 3MA-exposed cells (Fig. 3bi, bii). 
Cells were mostly present in interphase. Actinomy-
cin D-treated cells showed a decrease in cell density for 
both MCF-7 (Fig. 3ci) and MDA-MB-231 (Fig. 3cii) cells. 
Apoptotic body formation, cell debris and shrunken cells 
were visible, which are characteristic of apoptotic cell 
death. ESE-15-ol-treated MCF-7 (Fig.  3di) and MDA-
MB-231 (Fig.  3dii) cells demonstrated an increased 
proportion of rounded cells as well as the presence of 
apoptotic bodies. ESE-15-ol-treated cells together with 
3MA showed apoptotic body formation and rounded 
cells in both MCF-7 (Fig.  3ei) and MDA-MB-231 cells 
(Fig. 3eii), but to a lesser extend when compared to cells 
treated with ESE-15-ol without 3MA.
Acidic vacuoles were decreased in cells treated 
with ESE‑15‑ol in combination with 3MA
Monodansylcadaverine (MDC) is a weak base fluo-
rescent stain which stains acidic vacuoles that suggest 
occurence of autophagy [34]. MCF-7 and MDA-MB-231 
cells exposed to DMSO (Fig. 4ai, aii) and 3MA (Fig. 4bi, 
bii) showed non-specific MDC staining. Both controls 
displayed confluent cell growth. Tamoxifen-treated cells 
(Fig. 4ci, cii) showed an increase in MDC-stained vacu-
oles in both cell lines. ESE-15-ol-treated cells demon-
strated an increase in MDC-stained vacuoles, as well as 
decreased cell density (Fig.  4di, dii). ESE-15-ol treated 
cells in the presence of 3MA showed a decrease in MDC 
staining, with less acidic vacuole formation apparent 
when compared to the drug treated sample (Fig. 4ei, eii).
Vacuole formation in response to ESE‑15‑ol exposure was 
evident but diminshed when co‑incubated with 3MA
Transmission electron microscopy was used to ana-
lyze the ultrastructure of ESE-15-ol-treated MCF-7 and 
MDA-MB-231 cells, with and without autophagy inhibi-
tion by 3MA. Cells propagated in DMSO (Figs.  5a, 6a) 
showed a smooth cell membrane with minimal cellular 
protrusions, together with an intact nuclear envelope. 
No morphological differences were seen between cells 
exposed to DMSO and 3MA (Figs. 5b, 6b). Cells treated 
with actinomycin D (Figs.  5c, 6c) increased membrane 
blebbing and apoptotic body formation representative of 
apoptotic cell death. Tamoxifen-treated cells showed an 
increase in vesicle formation (Figs. 5d, 6d). Less vacuole 
formation was observed in tamoxifen-treated cells with 
3MA (Figs. 5e, 6e). This suggests partial autophagy inhi-
bition by 3MA. Intact cell membranes were observed in 
tamoxifen-treated cells, with and without 3MA. ESE-
15-ol-treated cells (Figs.  5f, 6f ) displayed an increase in 
vacuolar structures indicative of autophagy. Apoptotic 
bodies, hypercondensed chromatin and increased cell 
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protrusions were also observed in cells exposed to ESE-
15-ol. ESE-15-ol-treated cells with 3MA inhibition of 
autophagy (Figs. 5g, 6g) revealed cells with intact nuclear- 
and cell-membranes. A decrease in cellular distress with 
fewer vesicles was observed in these cells.
3MA co‑incubation increased cell viability and reduced 
G2/M block as well as the sub‑G1 population in response 
to ESE‑15‑ol exposure
The quantification of cells at various stages within the 
cell cycle was determined with flow cytometry. Cell cycle 
distribution of MCF-7 cells exposed to DMSO (Fig. 7ai) 
showed an average of 3.24 ± 0.54% in the sub-G1 phase, 
56.2 ± 4.89% in the G1 phase and 18.79 ± 0.89% in the 
G2/M phase. Cell cycle distribution of MDA-MB-231 
cells grown in DMSO (Fig.  7aii) showed an average of 
2.53 ±  1.62% in the sub-G1 phase, 57.8 ±  0.61% in the 
G1 phase and 29.5 ±  1.83% in the G2/M phase. No sta-
tistical significance was found between cells grown in 
medium only and treated with DMSO or 3MA, indicat-
ing that the vehicle was non-toxic to the cells. MCF-7 
and MDA-MB-231 cells exposed to actinomycin D 
and ESE-15-ol had statistically significant changes in 
their cell cycle distributions when compared to the 
DMSO vehicle control. Actinomycin D-treated MCF-7 
cells (Fig.  7bi) had a significant increase in the sub-
G1 phase (9.47  ±  0.31%; P  =  0.00015) and the G2/M 
(22.98  ±  2.32%; P  =  0.04) phase. ESE-15-ol-treated 
MCF-7 cells (Fig.  7ci) had a significant increase in the 
sub-G1 phase (18.14 ± 2.81%; P = 0.001) and the G2/M 
phase (60.28 ± 1.34%; P = 0.0009) when compared to the 
DMSO control. ESE-15-ol-treated MCF-7 cells together 
with 3MA autophagy inhibition (Fig. 7di) had a statisti-
cally significant increase in the G1 phase (35.70 ± 7.45%; 
P  =  0.02) when compared to ESE-15-ol without 3MA 
treatment (13.59 ± 0.36%). Actinomycin D treated MDA-
MB-231 cells (Fig. 7bii) had a significant decrease in the 
G1 phase (31.94 ±  2.75%; P =  0.0004) and concomitant 
increase in the G2/M phase (48.52  ±  2.63%; P  =  0.02) 
when compared to DMSO-exposed cells. ESE-15-ol-
treated MDA-MB-231 cells (Fig.  7cii) had a significant 
decrease in the G1 phase (44.45 ± 1.59%; P = 0.008) with 
a significant increase in the G2/M phase (43.23 ± 2.13%; 
P  =  0.009) when compared to DMSO vehicle control. 
ESE-15-ol-treated MDA-MB-231 cells with a concur-
rent treatment with 3MA (Fig. 7dii) had a statistically sig-
nificant increase in the G1 phase (63.64 ± 4.46%; P 0.03) 
when compared to cells exposed to ESE-15-ol without 
Fig. 2 Cytotoxicity study for ESE-15-ol with/without 3MA over a 24 h exposure period in MCF-7 and MDA-MB-231 breast cancer cells. a The dose 
dependent curve for MCF-7 cells showed an IG50 of 0.15 μM for ESE-15-ol with 3MA and 0.05 μM for ESE-15-ol only (P-value = 0.007); b MDA-
MB-231 cells showed an IG50 of 0.13 μM for ESE-15-ol with 3MA and 0.065 μM for ESE-15-ol only (P-value = 0.0195). Bars indicate averages of three 
independent biological repeats, each with n = 3. Error bars represent standard deviation
(See figure on next page.) 
Fig. 3 PlasDIC images of MCF-7 and MDA-MB-231 cells exposed to the compound with/or without 3MA for 24 h. i MCF-7 cells and ii MDA-MB-231 
cells grown in a DMSO and b 3MA served as negative controls. Confluent cell growth with no signs of cell distress was demonstrated. c Actino-
mycin D (0.1 μg/ml) served as a positive control for apoptosis, resulting in apoptotic body formation and compromised cell density. d ESE-15-ol-
treated cells revealed the presence of rounded cells, formation of apoptotic bodies and decreased cell density. e ESE-15-ol exposure to cells in 
which autophagy had been inhibited with 3MA showed an increase in cell viability. (Arrow colour key: Yellow = interphase cells; orange = rounded 
cells in metaphase; white = apoptotic bodies.)
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3MA. These results indicate that autophagy inhibition 
decreases the cytotoxic effect of ESE-15-ol exposure in 
MCF-7 and MDA-MB-231 breast cancer cells.
Apoptosis induction in response to ESE‑15‑ol was 
diminshed with addition of 3MA
Flow cytometry employing annexin V-FITC and PI was 
used to distinguish between viable-, apoptotic- and 
necrotic cells. Statistical analysis of dot plots data indi-
cated a statistically significant increase in apoptosis 
in actinomycin D-treated (Fig.  8bi) (40.06  ±  5.55%; 
P  =  0.001) and ESE-15-ol-treated (Fig.  8ci) 
(21.21 ± 0.13%; P = 0.002) MCF-7 cells when compared 
to the DMSO-vehicle control (Fig. 8ai). A statistically sig-
nificant increase in apoptosis in actinomycin D-treated 
(Fig.  8bii) (25.39  ±  3.44%; P  =  0.0006) and ESE-15-
ol-treated (Fig.  8cii) MDA-MB-231 cells (38  ±  7.02%; 
P = 0.004) was detected when compared to the DMSO-
vehicle control (Fig.  8aii). No statistically significant 
difference in viability was detected between cells grown 
in medium only, DMSO-exposure and 3MA-exposure 
in both MCF-7 and MDA-MB-231 cells. A statistically 
significant increase in viability in ESE-15-ol-treated 
MCF-7 and MDA-MB-231 cells together with 3MA 
(81.31  ±  2.05%; P  =  0.01 and 83.97  ±  5.6%; P  =  0.01, 
respectively) was observed when compared to ESE-15-ol-
treated cells (Fig. 8ei, eii).
LC3 expression was increased in cells exposed to ESE‑15‑ol
Flow cytometry employing a microtubule-associated 
protein 1A/1B-light chain 3 (LC3) conjugated rabbit 
polyclonal anti-LC3B antibody (Novus Biologicals, Lit-
tleton, CO) was used to quantify and confirm induc-
tion and inhibition of autophagy. Figure 9a illustrates an 
overlay histogram of MCF-7 (1) and MDA-MB-231(2) 
cells exposed to ESE-15-ol with and without 3MA. 
A right shift is seen in ESE-15-ol-treated cells with-
out 3MA. A decrease in LC3 detection is seen in cells 
(See figure on previous page.) 
Fig. 4 Fluorescent microscopy with monodansylcadaverine staining of MCF-7 and MDA-MB-231 cells. i MCF-7 and ii MDA-MB-231 cells treated 
with a DMSO and b 3MA served as negative controls and displayed non-specific MDC staining. c Tamoxifen was used as a positive control for 
acidic vacuoles and displayed clear MDC stained vacuoles. d ESE-15-ol treated cells showed increased MDC staining, while e ESE-15-ol treated cells 
together with 3MA showed less distinctive MDC staining, indicating partial autophagy inhibition (40× magnification)
Fig. 5 Transmission electron micrographs of MCF-7 cells. MCF-7 cells treated with a DMSO and b 3MA showed intact nuclear envelope and cyto-
plasmic membranes with minimal cell protrusions. c Actinomycin D-exposed cells showed membrane blebbing and apoptotic body formation. d 
Tamoxifen-treated cells showed an increase in vesicle formation when compared to e tamoxifen with 3MA. f ESE-15-ol-treated cells showed hyper-
condensed chromatin with an increase in vesicle- and apoptotic body formation. g Cells exposed to ESE-15-ol concurrent to autophagy inhibition 
with 3MA showed less signs of cell distress, fewer vesicles and intact nuclear membranes (Scale bar 5 μM) (Arrow colour keys: white = intact nuclear 
membrane; red = apoptotic bodies; yellow = vesicles)
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exposed to ESE-15-ol together with 3MA indicating 
partial autophagy inhibition. No difference was detected 
between cells grown in medium only and cells exposed 
to the DMSO vehicle control and 3MA (not shown in 
overlay). Graphical representations in Fig.  9b show a 
statistically significant fold increase of 2.075 ± 0.05 LC3 
after tamoxifen exposure and 1.67  ±  0.17 LC3 in ESE-
15-ol when compared to the DMSO vehicle control. A 
statistically significant fold decrease of LC3 is seen after 
tamoxifen with 3MA exposure (1.40 ±  0.25; P =  0.022) 
when compared to tamoxifen exposure alone, as well as 
between ESE-15-ol with 3MA (1.13 ±  0.11; P =  0.004) 
when compared to ESE-15-ol alone.  
LC3I conversion to LC3II decreased in cells treated 
with ESE‑15‑ol together with 3MA
LC3II has a role in cytoplasmic cargo selection, 
autophagosome membrane tethering and fusion [35]. 
Increased levels of LC3-II may be associated with an up-
regulation in autophagy or a decrease in turnover (altered 
autophagic flux). Western blots were used to quantify 
the formation of LC3II in the presence of the analogue 
with- and without 3MA (Fig. 10). Protein quantification 
revealed a statistically significant fold-increase in LC3II 
expression when MCF-7 cells were exposed to ESE-
15-ol (1.23 ± 0.11, P = 0.02) and tamoxifen (2.55 ± 0.35, 
P =  0.003, as did the MDA-MB-231 cells (2.75 ±  0.35, 
P = 0.002 and 2.4 ± 0.42, P = 0.004 respectively), when 
compared to the DMSO control. Addition of 3MA 
reduced LC3II expression to 0.73  ±  0.09-fold (MCF-7 
cells) and to 1.4 ± 0.56 (MDA-MB-231 cells), statistically 
significant when compared to ESE-15-ol only-exposed 
MCF-7 (P =  0.015) and MDA-MB-231 cells (P =  0.04) 
respectively. Similar trends were seen in the tamoxifen-
treated positive control samples.
Discussion
2ME is an anti-proliferative agent which shows prom-
ise in cancer treatment, including breast cancer [36]. It 
induces both the intrinsic- and extrinsic apoptotic path-
ways through inactivation of Bcl-2 and increased DR5 
expression [5]. Several promising analogues of 2ME, 
such as 2-methoxyestradiol-bis-sulfamate (2MEOE2bis-
MATE) have been developed for improved potency and 
bioavailability of the parent drug [9, 36, 37]. Our labo-
ratory has in silico-designed a range of sulphamoylated 
estrone analogues with the added intention to localise 
them to solid tumour micromilieus through an increased 
CAIX binding affinity [9, 38].
Of these compounds, ESE-15-ol, 2-ethyl-3-O-sul-
phamoyl-etsra-1,3,5 (10) 15-tetraene-3-ol-17-one (ESE-
15-one) and 2-ethyl-3-O-sulphamoyl-etsra-1,3,5 (10) 
16-tetraene (ESE-16) have been investigated for modes 
of cell death induction (apoptosis and autophagy) on 
Fig. 6 Transmission electron micrographs of MDA-MB-231 cells. MDA-MB-231 cells treated with a DMSO and b 3MA showed an intact nuclear 
membrane and well-defined cell membranes with minimal cell protrusions. c Actinomycin D-exposed cells showed membrane blebbing and 
apoptotic body formation. d Tamoxifen-treated cells showed more vesicle formation when compared to cells treated with e tamoxifen with 3MA. 
f ESE-15-ol-treated cells showed hyper condensed chromatin with increased vesicles and apoptotic body formation. g Cells exposed to ESE-
15-ol with 3MA showed fewer vesicles with an intact nuclear membrane (Scale bar 5 μM) (Arrow colour keys: white = intact nuclear membrane; 
red = apoptotic bodies; yellow = vesicles)
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Fig. 7 Cell cycle analysis of MCF-7 and MDA-MB231 cells exposed to ESE-15-ol with- and without 3MA. Cells were exposed to DMSO as a negative 
vehicle control (ai, aii) which showed a prominent G1 phase. Actinomycin D (bi, bii) was used as a positive control for apoptosis which resulted 
in an increase in the sub-G1 phase. An increase in the G2/M phase was seen in ESE-15-ol-treated cells (ci, cii) with a concurrent decrease in the 
G1 phase. ESE-15-ol treated cells together with 3MA (di, dii) showed a decrease in the G2/M phase with an increase in the G1 phase. Graphical 
representation of ei MCF-7 and eii MDA-MB-231 cell cycle analysis. ESE-15-ol-treated cells together with 3MA demonstrated an increase in the G1 
phase when compared to ESE-15-ol-treated cells (P value <0.05; standard deviation represented by T-bars; *indicates statistical difference between 
compounds and DMSO vehicle control; #indicates statistical difference between ESE-15-ol and ESE-15-ol with 3MA)
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Fig. 8 Annexin-V FITC flow cytometric analysis of cell viability. Dot blots of i MCF-7 and ii MDA-MB-231 cells exposed to a DMSO as a vehicle 
control and demonstrated a viable cell population. Dot blots of b actinomycin D (positive apoptosis control) and c ESE-15-ol-treated cells showed 
increased cell death via apoptosis. d ESE-15-ol-treated cells with 3MA showed increased cell viability when compared to cells exposed to ESE-15-ol 
only. Graphical representation of (ei) MCF-7 and (eii) MDA-MB-231 cells showed a decrease in cell viability in cells treated with ESE-15-ol when com-
pared to DMSO. An increase in viable cells is observed in ESE-15-ol treated cells with 3MA when compared to ESE-15-ol treated cells. Bars represent 
averages of three biological repeats (P value <0.05; standard deviations represented by T-bars; *indicates statistical difference between compounds 
and DMSO vehicle control; #indicates statistical difference between ESE-15-ol and ESE-15-ol with 3MA) (Dot plot keys: i = viable cells; ii = necrosis; 
iii = late apoptosis; iv early apoptosis)
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various cancer cell lines [9, 36, 39–41]. Authors have 
indicated the increased presence of autophagic vesicles 
at certain time points after drug exposure [42]. Exten-
sive analysis of the drug’s effect on induction or flux of 
autophagy have not been completed, although up-regu-
lation of autophagic genes have been reported on micro-
arrays [42]. Descriptions of autophagy conceptualize a 
dual role within the context of cellular survival, either 
inducing programmed cell death type II or activating a 
pro-survival phenotype [19]. Autophagy can be activated 
by tumor microenvironments to protect hypoxic and 
nutrient deprived cells, thus inducing resistance to drug 
treatment [43]. The current study aimed to determine 
the role of autophagy associated demonstrated on cancer 
cell exposure to ESE-15-ol by inhibiting autophagy with 
3MA.
Fig. 9 LC3 fluorescence determination within MCF-7 and MDA-MB-231 cells after a 24 h exposure. Overlay histogram of ai MCF-7 and aii MDA-
MB-231 exposed cells. Cells treated with ESE-15-ol showed a right shift which was greater than ESE-15-ol with 3MA. b Graphical representation 
shows an increase in LC3 detection within ESE-15-ol-treated cells. Bars represent averages of three biological repeats (P value <0.05; standard 
deviations represented by T-bars; *indicates statistical differences between compounds and DMSO vehicle control; #indicates statistical difference 
between ESE-15-ol and ESE-15-ol with 3MA; †indicates statistical difference between tamoxifen and tamoxifen with 3MA)
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Cytotoxicity studies on MCF-7 and MDA-MB-231 
breast adenocarcinoma cells were conducted over a 24 h 
period by spectrophotometric quantification of crys-
tal violet. IG50 values were determined for ESE-15-ol-
treated cells, and compared to the value obtained when 
5 mM 3MA, an inhibitor of autophagy, was added for the 
duration of the drug exposure. This was done to deter-
mine the effect which autophagy inhibition would have 
on the cytotoxicity of ESE-15-ol on MCF-7 and MDA-
MB-231 cells. IG50 values of 0.05 and 0.065 μM were cal-
culated for MCF-7 and MDA-MB-231 cells respectively 
when exposed to ESE-15-ol without 3MA. IG50 values 
of 0.15 and 0.1  μM in MCF-7 and MDA-MB-231 cells 
respectively were determined for ESE-15-ol together 
with 3MA. The increase in IG50 values with the addition 
of 3MA were statistically significant in both cell lines 
(P = 0.007; P = 0.0195). ESE-15-ol without 3MA had an 
increased cytotoxicity than with 3MA. The results indi-
cate the possibility that autophagy contributes to the cell 
death process in cells exposed to ESE-15-ol.
Various microscopic techniques were used to deter-
mine the effect of autophagy inhibition on the mor-
phology of MCF-7 and MDA-MB-231 cells after 
ESE-15-ol-exposure. PlasDIC microscopy revealed that 
ESE-15-ol-exposure resulted in numerous rounded 
cells, most likely in mitotic arrest, supporting its action 
Fig. 10 Western blot analysis of LC3II protein expression levels. Western blots of ai MCF-7 and aii MDA-MB-231 cells treated with ESE-15-ol showed 
a more prominent LC3II band than cells treated with ES-15-ol with 3MA. b Graphical representation demonstrates a statistically significant decrease 
in LC3II protein levels within cells exposed to ESE-15-ol concurrently with 3MA as well as tamoxifen with 3MA. Bars represent averages of three 
biological repeats (P value <0.05; standard deviations represented by T-bars; *indicates statistical differences between compounds and DMSO 
vehicle control; #indicates statistical difference between ESE-15-ol and ESE-15-ol with 3MA; †indicates statistical difference between tamoxifen and 
tamoxifen with 3MA)
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as a spindle poison. Cell cycle analysis corroborated this 
induction due to an increase in cells present in the G2/M 
phase. Previous studies have reported that a mitotic 
block was caused in MCF-7 cells exposed to 1 μM 2ME, 
the parent compound of ESE-15-ol [5]. Apoptotic bodies 
and shrunken cells were visualized on the micrographs 
of ESE-15-ol-exposed cells. This suggests that ESE-
15-ol induced cell death via apoptosis over a 24 h expo-
sure period due to spindle disruption. Theron et al. [11] 
showed that ESE-16-ol and ESE-15-one induced meta-
phase block due to abrogation of microtubule dynamics 
and non-satisfaction of the spindle assembly checkpoint 
(SAC), thereby inducing apoptosis in MDA-MB-231 and 
HeLa cells. In this study, only a small proportion of cells 
demonstrated a mitotic arrest, although apoptotic bodies 
were still visible when cells were treated with ESE-15-ol 
combined with 3MA (an effect which was more subtle 
when compared to cells exposed to the compound-only). 
Thus signs of apoptotic cell death were still present when 
autophagy was inhibited. For optimal cell death by ESE-
15-ol both apoptosis and autophagy are hypothesized to 
be involved.
Fluorescent microscopy employing MDC was used 
to detect acidic vacuoles that may be indicative of 
autophagy. MCF-7 and MDA-MB-231 cells treated with 
ESE-15-ol over a 24  h period showed positive stain-
ing for MDC, with more discrete vacuolar formation. 
Cells treated with ESE-15-ol in combination with 3MA 
showed a decrease in MDC staining when compared to 
cells treated with ESE-15-ol alone. This indicates that 
3MA blocked autophagy induced by ESE-15-ol, albeit 
incompletely. TEM was conducted to investigate the 
effects of ESE-15-ol as well as, autophagy inhibition on 
the ultrastructure of MCF-7 and MDA-MB-231 cells. 
Cells exposed to ESE-15-ol and tamoxifen (positive con-
trol) showed an increased number of vacuoles which are 
indicative autophagic vacuoles. Apoptotic bodies were 
observed in ESE-15-ol-treated cells, together with cel-
lular distress, chromatin hypercondensation and mem-
brane blebbing, indicating cell death via apoptosis. Cells 
exposed to ESE-15-ol together with 3MA demonstrated 
significantly less distress and a decrease in vacuole 
formation.
Apoptotic characteristics observed in the morphology 
studies of the drug-exposed cells were quantified using 
flow cytometry. Analysis of cell cycle progression showed 
a statistically significant decrease in mitotic arrest when 
MCF-7 and MDA-MB-231 cells were treated with ESE-
15-ol with 3MA when compared to ESE-15-ol without 
3MA. A statistically significant increase in the G1 phase 
was also demonstrated when cells were treated with ESE-
15-ol with 3MA when compared to ESE-15-ol without 
3MA. Quantification of the translocation of PS to the 
outer membrane of the cell during apoptosis was also 
done by flow cytometry. ESE-15-ol-exposed cells showed 
an increase in apoptosis to 21.21% for MCF-7 cells and 
38% for MDA-MB-231 cells with a decrease in cell via-
bility. Autophagy inhibition demonstrated a decrease in 
apoptosis (16.13% for MCF-7 cells and 6.74% for MDA-
MB-231 cells). This suggests that 3MA increased cell via-
bility when combined with ESE-15-ol.
Flow cytometry studies employing LC3 detection 
were used to quantify the presence of autophagic vacu-
oles. MCF-7 and MDA-MB-231 cells treated with ESE-
15-ol showed a significant fold increase in LC3 detection 
when compared to the DMSO vehicle control. Addition-
ally, 3MA inhibition of autophagy were quantified and 
verified in tamoxifen-treated cells. The decrease of acidic 
vacuoles seen with MDC staining of ESE-15-ol treated 
cells with 3MA as well as the TEM findings were corrob-
orated by the decrease in LC3 detection via flow cytome-
try. These results verified that 3MA incompletely blocked 
autophagy. LC3 is a marker for autophagic induction or 
to detect a decrease in autophagosome formation, but 
does however, have limitations. There are multiple iso-
forms of LC3 (LC3A, LC3B, LC3B2 and LC3C), as well 
as variation in the antibody specificity (LC3I vs LC3II). 
ATG8-PE/LC3II is a protein marker which detects com-
pleted autophagosome formation but does not measure 
or quantify autophagy flux (flow cytometry indicative of 
total LC3 levels and does not differentiate between LC3I 
and LC3II). Autophagic flux is often quantified via LC3-
II turnover as detected by Western blotting [44]. When 
co-incubated with the autophagy inhibitor 3MA, the 
decreased LC3II expression in comparison to the ele-
vated expression induced by ESE-15-ol, alludes to a dis-
ruption in autophagic flux, although these results must 
be interpreted with cauation due to the analytic con-
straints of autophagy quantification. This study indicated 
that the drug treatment did increase the LC3II expres-
sion, a response which was muted by co-incubation with 
3MA.
Autophagosomes are transported to the microtubule-
organising centre (MTOC) of cells along the microtubules 
where lysosome cluster are found [45]. In the MTOC, 
lysosome fusion and content exchange occurs after which 
autophagosomal degradation by lysosomal hydrolases 
take place [45]. It is hypothesised that ESE-15-ol increases 
the induction of autophagy, possibly by the increased for-
mation of reactive oxygen species [6]. Microarray analy-
sis of autophagy gene expression indicated up-regulation 
of autophagy-related genes after exposure to 17-beta 
estradiol analogues [42]. However, ESE-15-ol disrupts 
microtubule dynamics which are essential for autophagy, 
potentially retracting autophagosome fusion and deg-
radation. A possible explanation for the induction of 
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autophagy by ESE-15-ol could be the inhibition of bec-
lin-1. 3MA can possibly increase beclin-1 expression 
causing autophagy inhibition. These results support previ-
ous studies done with estradiol analogues and 2ME that 
indicate a molecular crosstalk between apoptosis and 
autophagy [36]. In addition, the exact effect that 3MA 
may have on the cells in the combination treatment would 
need to be determined (such as induction of p70S6K 
activity [46]). As inhibitors of PI3K, the loss of this sig-
nalling cascade may have further reaching consequences 
than just autophagy inhibition itself. Further investigation 
needs to be done to determine whether the increase in 
autophagosomes observed during ESE-15-ol exposure is 
due to an increase in autophagy induction or due to abro-
gated flux (fusion or degradation).
Conclusions
Data from this study supports the concept that the novel 
17-β-estradiol analogue, ESE-15-ol, induces both apop-
tosis and autophagy in MCF-7 and MDA-MB-231 cells. 
Results obtained from the morphological studies indi-
cated that 3MA incompletely blocked autophagy, and 
thereby increased cell survival. Flow cytometry was used 
to quantify the autophagy inhibition and increased cell 
viability. This in  vitro study revealed that 3MA-medi-
ated inhibition of autophagy increased cell viability of 
MCF-7 and MDA-MB-231 cells when exposed to ESE-
15-ol. Thus it is proposed that the ESE-15-ol-induced 
autophagic process in MCF-7 and MDA-MB-231 cells 
contributes to the novel compounds’ cytotoxic effect by 
inducing programmed cell death type II, as opposed to 
conferring resistance to the neoplastic cells to drug expo-
sure as a mechanism to compensate for cellular distress. 
Further quantification of the contribution of autophagy 
in cell death induction in response to the novel com-
pound, as well as its role in possible tumor resistance will 
be carried out in future in vitro and in vivo studies.
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